144 related articles for article (PubMed ID: 38745855)
1. Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.
Abdelaal AM; Sohal IS; Iyer SG; Sudarshan K; Orellana EA; Ozcan KE; Dos Santos AP; Low PS; Kasinski AL
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102193. PubMed ID: 38745855
[TBL] [Abstract][Full Text] [Related]
2. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
5. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
6. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
[TBL] [Abstract][Full Text] [Related]
7. A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.
Abdelaal AM; Sohal IS; Iyer S; Sudarshan K; Kothandaraman H; Lanman NA; Low PS; Kasinski AL
Oncogene; 2023 Sep; 42(40):2985-2999. PubMed ID: 37666938
[TBL] [Abstract][Full Text] [Related]
8. The RNA-binding protein SART3 promotes miR-34a biogenesis and G
Sherman EJ; Mitchell DC; Garner AL
J Biol Chem; 2019 Nov; 294(46):17188-17196. PubMed ID: 31619517
[TBL] [Abstract][Full Text] [Related]
9. Tobacco mosaic virus for the targeted delivery of drugs to cells expressing prostate-specific membrane antigen.
Shukla S; Marks I; Church D; Chan SK; Pokorski JK; Steinmetz NF
RSC Adv; 2021 Jun; 11(33):20101-20108. PubMed ID: 34178308
[TBL] [Abstract][Full Text] [Related]
10. Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin.
Orellana EA; Abdelaal AM; Rangasamy L; Tenneti S; Myoung S; Low PS; Kasinski AL
Mol Ther Nucleic Acids; 2019 Jun; 16():505-518. PubMed ID: 31071527
[TBL] [Abstract][Full Text] [Related]
11. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
[TBL] [Abstract][Full Text] [Related]
12. Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer.
Wu J; Lee HJ; You L; Luo X; Hasegawa T; Huang KC; Lin P; Ratliff T; Ashizawa M; Mei J; Cheng JX
Small; 2020 May; 16(19):e2001215. PubMed ID: 32307923
[TBL] [Abstract][Full Text] [Related]
13. Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy.
Jang E; Kim E; Son HY; Lim EK; Lee H; Choi Y; Park K; Han S; Suh JS; Huh YM; Haam S
Biomaterials; 2016 Oct; 105():12-24. PubMed ID: 27497057
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis.
Li YL; Liu XM; Zhang CY; Zhou JB; Shao Y; Liang C; Wang HM; Hua ZY; Lu SD; Ma ZL
Oncogenesis; 2017 Aug; 6(8):e372. PubMed ID: 28825720
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells.
Urgard E; Brjalin A; Langel Ü; Pooga M; Rebane A; Annilo T
Nucleic Acid Ther; 2017 Oct; 27(5):295-302. PubMed ID: 28657476
[TBL] [Abstract][Full Text] [Related]
16. Bone targeted miRNA delivery system for miR-34a with enhanced anti-tumor efficacy to bone-associated metastatic breast cancer.
Han TY; Hou LS; Li JX; Huan ML; Zhou SY; Zhang BL
Int J Pharm; 2023 Mar; 635():122755. PubMed ID: 36801480
[TBL] [Abstract][Full Text] [Related]
17. LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a.
Liang J; Li Y; Daniels G; Sfanos K; De Marzo A; Wei J; Li X; Chen W; Wang J; Zhong X; Melamed J; Zhao J; Lee P
Mol Cancer Res; 2015 Apr; 13(4):681-8. PubMed ID: 25587085
[TBL] [Abstract][Full Text] [Related]
18. Fluorescent nanodiamonds as innovative delivery systems for MiR-34a replacement in breast cancer.
Abate M; Lombardi A; Luce A; Porru M; Leonetti C; Bocchetti M; Campani V; De Rosa G; Graziano SF; Nele V; Cardile F; Marino FZ; Franco R; Ronchi A; Scrima M; Sperlongano R; Alfano R; Misso G; Amler E; Caraglia M; Zappavigna S
Mol Ther Nucleic Acids; 2023 Sep; 33():127-141. PubMed ID: 37449042
[TBL] [Abstract][Full Text] [Related]
19. miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.
Han Y; Meng F; Venter J; Wu N; Wan Y; Standeford H; Francis H; Meininger C; Greene J; Trzeciakowski JP; Ehrlich L; Glaser S; Alpini G
J Hepatol; 2016 Jun; 64(6):1295-304. PubMed ID: 26923637
[TBL] [Abstract][Full Text] [Related]
20. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
